David D. Meek - 19 Dec 2022 Form 4 Insider Report for Mirati Therapeutics, Inc.

Role
Chief Executive Officer, Director
Signature
/s/ Reena R. Desai, Attorney-in-Fact
Issuer symbol
N/A
Transactions as of
19 Dec 2022
Net transactions value
-$186,552
Form type
4
Filing time
21 Dec 2022, 20:20:26 UTC
Previous filing
11 Jul 2022
Next filing
19 Jan 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction MRTX Common Stock Award $0 +35,425 +104% $0.000000 69,587 19 Dec 2022 Direct F1, F2
transaction MRTX Common Stock Sale $186,552 -4,616 -6.6% $40.41 64,971 21 Dec 2022 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Award of Performance Stock Units ("PSUs"). 1/3 of the PSUs have vested on December 19, 2022 (one week after the "Achievement Date" of December 12, 2022). 1/3 of the remaining shares will vest on the one year anniversary of the Achievement Date and the remaining 1/3 will vest on the two year anniversary of the Achievement Date, subject to Mr. Meek's continuous service.
F2 Includes 64 shares acquired under the ESPP Purchase on 5/31/2022 and 41 shares acquired under the ESPP purchase on 11/30/2022.
F3 Represents shares sold by the Company to satisfy the tax withholding obligation associated with the vesting of a portion of the PSUs referenced in Footnote 1.